SEARCH

SEARCH BY CITATION

  • 1
    . Which statement about weight loss is incorrect?
  • a
    ) In the Diabetes Prevention Program study, subjects who implemented lifestyle changes lost weight in the 1st year and regained about one-third of it in the following 3 years.
  • b
    ) Losing weight and gaining it back has some health advantages.
  • c
    ) Typically, lifestyle modification programs ask patients to completely change their food habits.
  • d
    ) Walking is the most frequently recommended exercise activity in the Diabetes Prevention Program.
  • 2
    . Which statement is true about lifestyle modification?
  • a
    ) Patients treated by lifestyle modification may lose ∼10% of their body weight in 30 weeks of treatment.
  • b
    ) Regularly scheduled treatment visits are a critical component of lifestyle modification.
  • c
    ) Lifestyle modification regimens typically encourage patients to reduce energy intake by 500 to 1000 kcal/d.
  • d
    ) All of the above.
  • 3
    . Which statement about dietary approaches to weight loss is incorrect?
  • a
    ) Portion-controlled servings can eliminate the need to weigh foods and improve maintenance of weight loss.
  • b
    ) The underlying principle of low-energy diets is that the volume of food consumed, not its caloric content, influences satiety.
  • c
    ) Recent randomized controlled trials have found that in the short term, dieters could achieve greater weight loss on a high-protein, low-carbohydrate diet than on conventional low-fat diets.
  • d
    ) Members of the National Weight Control Registry generally eat a high-protein, low-carbohydrate diet.
  • 4
    . When drug treatment is necessary for obesity:
  • a
    ) Long-term therapy is usually not required.
  • b
    ) Long-term therapy is usually required.
  • c
    ) Pharmacotherapy alone is sufficient for long-term weight management.
  • d
    ) All prescription drugs available in the U.S. to treat obesity are approved for long-term use.
  • 5
    . The following is true regarding sibutramine and weight loss:
  • a
    ) Weight loss on sibutramine is dose-dependent.
  • b
    ) Weight loss in obese patients with obesity-related hypertension (controlled) or type 2 diabetes was greater than that observed in studies of subjects without comorbid disease.
  • c
    ) In the Sibutramine Trial of Obesity Reduction and Maintenance, subjects who continued on sibutramine after 6 months of initial sibutramine therapy maintained 20% of their initial weight loss after 2 years.
  • d
    ) Sibutramine lowers blood pressure.
  • 6
    . Clinical studies with orlistat have shown that:
  • a
    ) Treatment with orlistat resulted in a higher proportion of patients who achieved ≥ 5% or ≥ 10% weight loss than placebo.
  • b
    ) Orlistat has no effect on cholesterol.
  • c
    ) Treatment with orlistat and placebo resulted in similar rates of gastrointestinal side effects.
  • d
    ) All of the above.
  • 7
    . Which statement about obesity is true?
  • a
    ) Increase in severity of obesity increases the risk of mortality from diabetes and cardiovascular disease.
  • b
    ) Complications associated with obesity include hypertension and osteoarthritis.
  • c
    ) Patients who lose weight through dietary restriction, exercise, and a behavioral modification plan usually regain much of the weight lost in 1 year.
  • d
    ) All of the above.
  • 8
    . In the 6-month dose ranging study of topiramate:
  • a
    ) The two higher-dose topiramate groups showed a significantly greater weight loss than the placebo group.
  • b
    ) Weight loss was significantly less in the two higher- dose topiramate groups than in the two lower-dose groups.
  • c
    ) At 6 weeks, weight loss reached a plateau.
  • d
    ) Blood pressure decreased only in the topiramate groups.
  • 9
    . Data from the three topiramate clinical studies (6-month dose ranging study, long-term weight loss study, and long-term weight maintenance study) indicated:
  • a
    ) All topiramate doses resulted in a significant decrease in systolic and diastolic blood pressure.
  • b
    ) Only the highest dose of topiramate resulted in a significant decrease in both systolic and diastolic blood pressure.
  • c
    ) Topiramate had no effect on blood pressure.
  • d
    ) Only the placebo group showed improvement in baseline metabolic parameters.
  • 10
    . The World Health Organization definition of metabolic syndrome does not include:
  • a
    ) Central obesity.
  • b
    ) Microalbuminuria.
  • c
    ) Insulin resistance.
  • d
    ) Proinflammatory state.
  • 11
    . Which of the following statements about insulin resistance is true?
  • a
    ) In insulin resistance, insulin receptor activity is impaired.
  • b
    ) Insulin resistance in muscle leads to impairment of glucose oxidation and storage.
  • c
    ) Adiponectin synthesis is reduced in insulin resistance.
  • d
    ) All of the above.
  • 12
    . Which of the following statements regarding the management of metabolic syndrome is incorrect?
  • a
    ) Elevated triglycerides should be reduced.
  • b
    ) Low-density lipoprotein cholesterol is not considered a risk factor.
  • c
    ) High blood pressure is a serious concern and should be treated.
  • d
    ) It is difficult to adjust the levels of high-density lipoprotein cholesterol.